English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Cancer patients with distant metastasis have unfavorable prognoses, and systemic therapies have been the mainstream treatments for decades. Surgical resection and radiofrequency ablation have been considered as local curative options for limited metastatic lesions. With complete surgical resection of all metastatic lesions, the 5-year overall survival (OS) rate has been reported between 20% to 50% in patients with pulmonary metastasectomy and around 40% in patients with hepatic metastasectomy (1,2). Original Article

therapeutic radiology and oncology

Treatment outcomes and prognostic factor analyses in pulmonary or hepatic metastatic patients treated with stereotactic body radiation therapy—a single institution experience